Anti-influenza Drugs Market - Size and Forecast [2021-2031]
The Anti-influenza Drugs Market is expected to register a CAGR of 6.8% from 2024 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The report is segmented by Product Type (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and Other Products). The report further presents analysis based on the Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Anti-influenza Drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Anti-influenza Drugs Market Segmentation
Product Type- Peramivir
- Zanamivir
- Oseltamivir Phosphate
- Baloxavir Marboxil
- Other Products
- Retail Pharmacies
- Hospital Pharmacies
- Others
Strategic Insights
Anti-influenza Drugs Market Growth Drivers- Increasing frequency of Flu illness: An increasing incidence of influenza infections globally is one of the significant forces driving the anti-influenza drugs market. Such viral infections occurred in seasonal outbreaks and sometimes pandemics, as evidenced by the H1N1 outbreak of 2009 and the emergence of possibly new strains, and this demand for effective antiviral drugs is continually rising. In temperate areas of the world, the flu season typically recurs each year with considerable market upside.
- Advancements in Antiviral Drug Development: Antiviral drug development is another major driver. Companies are actively moving ahead with and discovering new medicines to work against new strains of influenza, and these have led to the introduction of new antiviral medicines like neuraminidase inhibitors-discovered so far are oseltamivir and zanamivir, which have restructured strategies toward treatment. Also, a growing inclination toward broad-spectrum antiviral therapy, where targeting will include a broad spectrum of influenza viruses, ensures the incoming arrival of new medicines onto the marketplace.
- Government Support and Vaccination Programs: Governments are now devoting increasing numbers of resources to the immunization of their populations against influenza and the use of therapeutics for its prevention and treatment. Thus, national healthcare entities such as the CDC and the WHO recommend antiviral drugs for high-risk populations. This produces increased demand for anti-influenza drugs and guarantees the inclusion of such medications in essential healthcare programs. In some countries, policy creation toward public health policies such as subsidized antivirals, which will further decrease the burden of influenza on the population, has boosted market growth.
- Increasing Combined therapy trends: Change from the single-drug use for antiviral therapy into duality, wherein different types of antiviral agents are being utilized put advancement in their efficacy and even reduce resistance. This trend develops into thorough advances against the constantly evolving and resistant strains of influenza viruses, which usually make single-target therapies less effective.
- Growing Interest to Broad-Spectrum Antiviral Drugs: As certain strains of viruses continue mutating, the focus has now been narrowed to broad-spectrum antiviral drugs with several viral strains. This evolution is attributed to the interest of such treatments from seasonal flu strains to pandemic strains. Research on drugs targeting a wider range of taxa, particularly those affecting other respiratory viruses such as coronaviruses, is also becoming a very active research thrust in antiviral drug development.
- Personalized Medicine Growing: This popular trend would impact the market for anti-influenza drugs as well. Personalized medicine affects the type of treatment design that goes into the particular genetic make-up, immune response, and other factors of an individual. Such importance is even more put into practice with influenza, which has so many different antiviral agents with varying effectiveness in individual patients. The development of biomarkers predicting drug responses would therefore be one key area to optimise treatment regimens for influenza.
- The Development of Non-Oral Anti-influenza Therapeutics: The development of non-oral anti-influenza therapeutics has generated a lot of interest; inhalers, nasal sprays, and intravenous formulations are some examples. These delivery mechanisms can be very preferred methods of drug administration for those patients who cannot take capsules or are otherwise needy and requiring immediate remedy, such as those confined in a hospital. Thus, the demand for alternative drug delivery systems is expected to continue growing and opportunities for the development of the drug market.
- Prophylactic Drugs and Long-Term Immunization: Market growth is expected in prophylactic anti-influenza drugs specifically dedicated to high-risk groups because they would include both the treaters and preventers of influenza infections. The increasing need to protect against longer-lasting immunity as a consequence of newly emerging viral strains further supports the understanding of these drugs. Such pharmaceuticals would probably gain popularity because they can offer condition and prevention in a single regimen.
- Biological and Gene Therapy: With genetics and biologics coming into their own, the investment therefore in future anti-influenza drugs becomes really very much alive. There is research going on with monoclonal antibodies and gene-editing technologies like CRISPR to target and neutralize influenza viruses more effectively. Really, these technologies are still a good way off from the starting line, but they might offer new, innovative approaches to prevention and therapy for influenza-especially under the circumstances of traditional antivirals failing or resistant.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Anti-influenza Drugs Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Anti-influenza Drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Anti-influenza Drugs Market is estimated to witness a CAGR of 6.8% from 2023 to 2031
The major factors driving the Anti-influenza Drugs market are:
1. Increasing frequency of Flu illness
2. Advancements in Antiviral Drug Development
Development of Non-Oral Anti-influenza Therapeutics act as a opportunity for growth of the market in forecast period.
North America region dominated the Anti-influenza Drugs market in 2023.
Oseltamivir Phosphate segment, by Product Type, dominated the market in 2023.
Players operating in the market are Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer, Inc., Cipla Inc., Merck KGaA, Bristol Myers Squibb, GlaxoSmithKline plc, Mylan N.V., Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Ltd
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Anti-influenza Drugs - By Product type
1.3.2 Anti-influenza Drugs - By Distribution channel
1.3.3 Anti-influenza Drugs - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTI-INFLUENZA DRUGS LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTI-INFLUENZA DRUGS - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANTI-INFLUENZA DRUGS - GLOBAL MARKET ANALYSIS
6.1. ANTI-INFLUENZA DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANTI-INFLUENZA DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. ANTI-INFLUENZA DRUGS - REVENUE AND FORECASTS TO 2028 - PRODUCT TYPE
7.1. OVERVIEW
7.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
7.3. PERAMIVIR
7.3.1. Overview
7.3.2. peramivir Market Forecast and Analysis
7.4. ZANAMIVIR
7.4.1. Overview
7.4.2. zanamivir Market Forecast and Analysis
7.5. OSELTAMIVIR PHOSPHATE
7.5.1. Overview
7.5.2. oseltamivir phosphate Market Forecast and Analysis
7.6. BALOXAVIR MARBOXIL
7.6.1. Overview
7.6.2. baloxavir marboxil Market Forecast and Analysis
7.7. OTHER PRODUCTS
7.7.1. Overview
7.7.2. other products Market Forecast and Analysis
8. ANTI-INFLUENZA DRUGS - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. RETAIL PHARMACIES
8.3.1. Overview
8.3.2. retail pharmacies Market Forecast and Analysis
8.4. HOSPITAL PHARMACIES
8.4.1. Overview
8.4.2. hospital pharmacies Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. others Market Forecast and Analysis
9. ANTI-INFLUENZA DRUGS REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Anti-influenza Drugs Overview
9.1.2 North America Anti-influenza Drugs Forecasts and Analysis
9.1.3 North America Anti-influenza Drugs Forecasts and Analysis - By Product type
9.1.4 North America Anti-influenza Drugs Forecasts and Analysis - By Distribution channel
9.1.5 North America Anti-influenza Drugs Forecasts and Analysis - By Countries
9.1.5.1 United States Anti-influenza Drugs
9.1.5.1.1 United States Anti-influenza Drugs by Product type
9.1.5.1.2 United States Anti-influenza Drugs by Distribution channel
9.1.5.2 Canada Anti-influenza Drugs
9.1.5.2.1 Canada Anti-influenza Drugs by Product type
9.1.5.2.2 Canada Anti-influenza Drugs by Distribution channel
9.1.5.3 Mexico Anti-influenza Drugs
9.1.5.3.1 Mexico Anti-influenza Drugs by Product type
9.1.5.3.2 Mexico Anti-influenza Drugs by Distribution channel
9.2. EUROPE
9.2.1 Europe Anti-influenza Drugs Overview
9.2.2 Europe Anti-influenza Drugs Forecasts and Analysis
9.2.3 Europe Anti-influenza Drugs Forecasts and Analysis - By Product type
9.2.4 Europe Anti-influenza Drugs Forecasts and Analysis - By Distribution channel
9.2.5 Europe Anti-influenza Drugs Forecasts and Analysis - By Countries
9.2.5.1 Germany Anti-influenza Drugs
9.2.5.1.1 Germany Anti-influenza Drugs by Product type
9.2.5.1.2 Germany Anti-influenza Drugs by Distribution channel
9.2.5.2 France Anti-influenza Drugs
9.2.5.2.1 France Anti-influenza Drugs by Product type
9.2.5.2.2 France Anti-influenza Drugs by Distribution channel
9.2.5.3 Italy Anti-influenza Drugs
9.2.5.3.1 Italy Anti-influenza Drugs by Product type
9.2.5.3.2 Italy Anti-influenza Drugs by Distribution channel
9.2.5.4 Spain Anti-influenza Drugs
9.2.5.4.1 Spain Anti-influenza Drugs by Product type
9.2.5.4.2 Spain Anti-influenza Drugs by Distribution channel
9.2.5.5 United Kingdom Anti-influenza Drugs
9.2.5.5.1 United Kingdom Anti-influenza Drugs by Product type
9.2.5.5.2 United Kingdom Anti-influenza Drugs by Distribution channel
9.2.5.6 Rest of Europe Anti-influenza Drugs
9.2.5.6.1 Rest of Europe Anti-influenza Drugs by Product type
9.2.5.6.2 Rest of Europe Anti-influenza Drugs by Distribution channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Anti-influenza Drugs Overview
9.3.2 Asia-Pacific Anti-influenza Drugs Forecasts and Analysis
9.3.3 Asia-Pacific Anti-influenza Drugs Forecasts and Analysis - By Product type
9.3.4 Asia-Pacific Anti-influenza Drugs Forecasts and Analysis - By Distribution channel
9.3.5 Asia-Pacific Anti-influenza Drugs Forecasts and Analysis - By Countries
9.3.5.1 Australia Anti-influenza Drugs
9.3.5.1.1 Australia Anti-influenza Drugs by Product type
9.3.5.1.2 Australia Anti-influenza Drugs by Distribution channel
9.3.5.2 China Anti-influenza Drugs
9.3.5.2.1 China Anti-influenza Drugs by Product type
9.3.5.2.2 China Anti-influenza Drugs by Distribution channel
9.3.5.3 India Anti-influenza Drugs
9.3.5.3.1 India Anti-influenza Drugs by Product type
9.3.5.3.2 India Anti-influenza Drugs by Distribution channel
9.3.5.4 Japan Anti-influenza Drugs
9.3.5.4.1 Japan Anti-influenza Drugs by Product type
9.3.5.4.2 Japan Anti-influenza Drugs by Distribution channel
9.3.5.5 South Korea Anti-influenza Drugs
9.3.5.5.1 South Korea Anti-influenza Drugs by Product type
9.3.5.5.2 South Korea Anti-influenza Drugs by Distribution channel
9.3.5.6 Rest of Asia-Pacific Anti-influenza Drugs
9.3.5.6.1 Rest of Asia-Pacific Anti-influenza Drugs by Product type
9.3.5.6.2 Rest of Asia-Pacific Anti-influenza Drugs by Distribution channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Anti-influenza Drugs Overview
9.4.2 Middle East and Africa Anti-influenza Drugs Forecasts and Analysis
9.4.3 Middle East and Africa Anti-influenza Drugs Forecasts and Analysis - By Product type
9.4.4 Middle East and Africa Anti-influenza Drugs Forecasts and Analysis - By Distribution channel
9.4.5 Middle East and Africa Anti-influenza Drugs Forecasts and Analysis - By Countries
9.4.5.1 South Africa Anti-influenza Drugs
9.4.5.1.1 South Africa Anti-influenza Drugs by Product type
9.4.5.1.2 South Africa Anti-influenza Drugs by Distribution channel
9.4.5.2 Saudi Arabia Anti-influenza Drugs
9.4.5.2.1 Saudi Arabia Anti-influenza Drugs by Product type
9.4.5.2.2 Saudi Arabia Anti-influenza Drugs by Distribution channel
9.4.5.3 U.A.E Anti-influenza Drugs
9.4.5.3.1 U.A.E Anti-influenza Drugs by Product type
9.4.5.3.2 U.A.E Anti-influenza Drugs by Distribution channel
9.4.5.4 Rest of Middle East and Africa Anti-influenza Drugs
9.4.5.4.1 Rest of Middle East and Africa Anti-influenza Drugs by Product type
9.4.5.4.2 Rest of Middle East and Africa Anti-influenza Drugs by Distribution channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Anti-influenza Drugs Overview
9.5.2 South and Central America Anti-influenza Drugs Forecasts and Analysis
9.5.3 South and Central America Anti-influenza Drugs Forecasts and Analysis - By Product type
9.5.4 South and Central America Anti-influenza Drugs Forecasts and Analysis - By Distribution channel
9.5.5 South and Central America Anti-influenza Drugs Forecasts and Analysis - By Countries
9.5.5.1 Brazil Anti-influenza Drugs
9.5.5.1.1 Brazil Anti-influenza Drugs by Product type
9.5.5.1.2 Brazil Anti-influenza Drugs by Distribution channel
9.5.5.2 Argentina Anti-influenza Drugs
9.5.5.2.1 Argentina Anti-influenza Drugs by Product type
9.5.5.2.2 Argentina Anti-influenza Drugs by Distribution channel
9.5.5.3 Rest of South and Central America Anti-influenza Drugs
9.5.5.3.1 Rest of South and Central America Anti-influenza Drugs by Product type
9.5.5.3.2 Rest of South and Central America Anti-influenza Drugs by Distribution channel
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ANTI-INFLUENZA DRUGS
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. ANTI-INFLUENZA DRUGS, KEY COMPANY PROFILES
12.1. ASTRAZENECA PLC
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BIOCRYST PHARMACEUTICALS, INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. DAIICHI SANKYO COMPANY, LIMITED.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. F. HOFFMANN-LA ROCHE LTD
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. GLAXOSMITHKLINE PLC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. MYLAN N.V.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. NOVARTIS AG
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. SANOFI
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SEQIRUS
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
- AstraZeneca plc
- BIOCRYST PHARMACEUTICALS, INC.
- DAIICHI SANKYO COMPANY, LIMITED.
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc.
- Mylan N.V.
- Novartis AG
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Seqirus
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For